Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Zacks Research increased their Q4 2024 earnings per share (EPS) estimates for Bio-Rad Laboratories in a report released on Thursday, February 6th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings of $2.87 per share for the quarter, up from their previous forecast of $2.86. The consensus estimate for Bio-Rad Laboratories' current full-year earnings is $10.33 per share. Zacks Research also issued estimates for Bio-Rad Laboratories' Q2 2025 earnings at $3.16 EPS.
Other analysts have also issued research reports about the company. Citigroup upped their target price on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. StockNews.com upgraded Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research note on Friday, November 1st. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $394.20.
Read Our Latest Research Report on BIO
NYSE:BIO opened at $341.69 on Monday. The firm has a 50-day simple moving average of $341.16 and a 200-day simple moving average of $336.87. Bio-Rad Laboratories has a one year low of $262.12 and a one year high of $387.99. The firm has a market cap of $9.57 billion, a P/E ratio of -12.50 and a beta of 0.90. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.52 and a current ratio of 6.14.
Institutional investors have recently added to or reduced their stakes in the business. Wealthfront Advisers LLC acquired a new position in Bio-Rad Laboratories in the 4th quarter worth approximately $342,686,000. Van ECK Associates Corp lifted its stake in Bio-Rad Laboratories by 97.8% in the 3rd quarter. Van ECK Associates Corp now owns 1,303,752 shares of the medical research company's stock worth $436,861,000 after purchasing an additional 644,530 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in Bio-Rad Laboratories in the 3rd quarter valued at $83,681,000. Wedge Capital Management L L P NC acquired a new stake in Bio-Rad Laboratories during the fourth quarter worth about $28,740,000. Finally, Mawer Investment Management Ltd. lifted its holdings in Bio-Rad Laboratories by 63.0% in the third quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company's stock valued at $72,900,000 after acquiring an additional 84,237 shares during the last quarter. Institutional investors and hedge funds own 65.24% of the company's stock.
Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Bio-Rad Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.
While Bio-Rad Laboratories currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.